Spotlight welcomes Biofrigas
Today is the first day of trading in Biofrigas, a Gothenburg-based company operating in the energy sector, - the fifth company to be listed on Spotlight Stock Market this year.
The company is currently working on the development of liquid biofuel. The technology is used to liquefy red gas into liquid biogas. The biogas can then be used for fuel for heavier vehicles such as trucks, buses and heavy shipping, as well as in the industrial sector.
“Biofrigas operates in a very interesting industry which is both important and where there is a great interest in alternative energy sources. We look forward to following Biofrigas’ journey with us.” says Emelie Jarnesten, Head of Business Operations at Spotlight
Prior to the listing, Biofrigas made a new share issue that was subscribed to approximately SEK 28.96 million, which corresponds to a subscription rate of 170 percent.
“We get two things in one: access to a stock market that can put a value on the company, and the opportunity to raise capital. The other thing that we have already seen is that it creates interest, it is a form of marketing for our products, we already see the effect of the work that is done and we get inquiries, which is really exciting. " Martin Lindé, Chairman of the Board of Biofrigas
"We have noticed a big interest, partly for the company, but also for this type of company that works with things that are good for the planet." says Jonas Stålhandske, CEO of Biofrigas.
A warm welcome to the Spotlight!
Press contact
Jenny Sondal, CMO Spotlight
+46 70 7749303, js@spotlightstockmarket.com
WHY SPOTLIGHT
Spotlight is the marketplace where investors and growth companies meet. At Spotlight it is easier and safer for companies to be listed. We offer an overall solution that increase the visibility for our companies through unique media collaborations. Investors get through Spotlight the opportunity to become shareholders in more than 170 growth companies from different businesses and countries, among those are Freetrailer, Hamlet Pharma and Synthetic MR.
